Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)

Historic Change in Receivables for Keros Therapeutics (KROS) over the last 5 years, with Q3 2025 value amounting to -$12.3 million.

  • Keros Therapeutics' Change in Receivables fell 330937.5% to -$12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 70000.0%. This contributed to the annual value of $2.6 million for FY2024, which is 171748.25% up from last year.
  • Keros Therapeutics' Change in Receivables amounted to -$12.3 million in Q3 2025, which was down 330937.5% from -$1.5 million recorded in Q2 2025.
  • Keros Therapeutics' Change in Receivables' 5-year high stood at $18.0 million during Q4 2021, with a 5-year trough of -$18.0 million in Q1 2022.
  • For the 5-year period, Keros Therapeutics' Change in Receivables averaged around $291000.0, with its median value being $91500.0 (2021).
  • The largest annual percentage gain for Keros Therapeutics' Change in Receivables in the last 5 years was 1742891.57% (2025), contrasted with its biggest fall of 330937.5% (2025).
  • Over the past 5 years, Keros Therapeutics' Change in Receivables (Quarter) stood at $18.0 million in 2021, then tumbled by 200.0% to -$18.0 million in 2022, then skyrocketed by 100.79% to $143000.0 in 2023, then skyrocketed by 1546.15% to $2.4 million in 2024, then tumbled by 623.53% to -$12.3 million in 2025.
  • Its Change in Receivables was -$12.3 million in Q3 2025, compared to -$1.5 million in Q2 2025 and $14.5 million in Q1 2025.